Progyny Reports Strong Q2 2026 Growth Amid Robust Selling Season — Progyny, Inc.

Event summary

Progyny reported a 5.3% year-over-year revenue increase to $350.5 million in Q2 2026.
Gross profit rose by 13% to $89.3 million, with gross margin expanding to 25.5%.
The company repurchased nearly 1.2 million shares for $31.5 million during the quarter.
Full-year revenue guidance is projected between $1.360 billion and $1.385 billion.

The big picture

Progyny's strong Q2 2026 results reflect sustained demand for women's health and family building solutions, particularly during the selling season. The company's ability to expand gross margins while investing in platform enhancements positions it favorably within the competitive healthcare benefits administration sector. However, navigating seasonal fluctuations and maintaining client retention will be pivotal in achieving its full-year financial outlook.

What we're watching

Client Retention: The company has mitigated retention risk with its largest accounts, but sustaining this momentum will be critical for future growth.
Seasonal Trends: Progyny expects a more pronounced seasonal impact on member activity in Q3 2026, which could affect short-term performance metrics.
Operational Efficiency: Continued improvements in care management services and platform investments will be key to maintaining gross margin expansion.